POU1F1 Antibody

^Unavailable

說明書

中文名稱：

POU1F1兔多克隆抗體
貨號：

CSB-PA018391LA01HU
規(guī)格：

￥880
圖片：
IHC image of CSB-PA018391LA01HU diluted at 1:600 and staining in paraffin-embedded human gastric cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) POU1F1 Polyclonal antibody
Uniprot No.：

P28069
基因名：

POU1F1
別名：

Dwarf antibody; GHF 1 antibody; GHF 1A antibody; GHF-1 antibody; GHF1 antibody; GHF1A antibody; Growth hormone factor 1 antibody; Hmp 1 antibody; Hmp1 antibody; Pit 1 antibody; Pit 1 beta antibody; PIT 1Z antibody; PiT-1 antibody; Pit1 beta antibody; PIT1_HUMAN antibody; PIT1Z antibody; Pituitary growth hormone antibody; Pituitary specific positive transcription factor 1 antibody; Pituitary-specific positive transcription factor 1 antibody; POU class 1 homeobox 1 antibody; POU domain class 1 transcription factor 1 antibody; POU domain transcriptional regulator antibody; POU1F1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Pituitary-specific positive transcription factor 1 protein (34-130AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:500-1:1000

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Transcription factor involved in the specification of the lactotrope, somatotrope, and thyrotrope phenotypes in the developing anterior pituitary. Specifically binds to the consensus sequence 5'-TAAAT-3'. Activates growth hormone and prolactin genes.
基因功能參考文獻：
1. Deletion in the POU1F1 gene is associated with Combined pituitary hormone deficiency. PMID: 28356564
2. This result strongly suggests the possibility, for the first time, that isolated mutations in the short isoform of POU1F1 could be sufficient for induction of POU1F1-related combined pituitary hormone deficiency. PMID: 27885216
3. High expression level of Pit-1 was significantly associated with poor overall survival of the patients (P=0.001) and Cox regression analysis indicated that Pit-1 might be a prognostic factor for breast cancer prognosis (HR=1.955, 95% CI=1.295-3.035, P=0.003). PMID: 27798557
4. The present study reports on screening of POU1F1, PROP1, and HESX1 in combined pituitary hormone deficiency patients and the novel variations identified. PMID: 27756091
5. A missense POU1F1 mutation is associated with isolated growth hormone deficiency. PMID: 26612202
6. Data identify silent subtype 3 adenomas as aggressive monomorphous plurihormonal adenomas of Pit-1 lineage that may be associated with hyperthyroidism, acromegaly or galactorrhea and amenorrhea. PMID: 26743473
7. investigated the specific mutations in PROP1, POU1F1, LHX3, and HESX1 genes in patients with combined pituitary hormone deficiency (CPHD) in Turkey PMID: 25500790
8. Pit-1 regulates MMP-1 and MMP-13, and that inhibition of MMP-13 blocked invasiveness to lung in Pit-1-overexpressed breast cancer cells. PMID: 25527274
9. These results suggest that the anti-PIT-1 antibody is not a cause but a marker of anti-PIT-1 antibody syndrome, in which cytotoxic T lymphocytes play a pivotal role in the pathogenesis. PMID: 24937538
10. New target genes of POU1F1 and downstream networks controlled by this factor. PMID: 22638072
11. Expression analysis of HMGA1, HMGA2 and PIT1 in human pituitary adenomas of different histological types revealed a direct correlation between PIT1 and HMGA expression levels. PMID: 22199144
12. This is the first report of a mutation at the exon 2 donor splice site of POU1F1, affecting TAD-R2. PMID: 21722153
13. HSII confers robust POU1F1-dependent activation of hGH-N in this system. PMID: 22094313
14. study, which identifies a novel loss-of-function mutation in POU1F1, describes the phenotype of a rare condition in a patient followed from the first weeks of life to adulthood PMID: 21521297
15. Data show no mutations in HESX1, PROP1, and POU1F1 genes, seven different mutations in CTNNB1 in 8/16 patients, and hyperexpression of miR-150. PMID: 21761366
16. Pit-1 overexpression or knockdown in human breast cancer cell lines induced profound phenotypic changes in the expression of proteins involved in cell proliferation, apoptosis, and invasion. PMID: 21060149
17. These results support the inference that W194XProp1 is unable to increase POU1F1 gene expression by the defect of transactivating domain and that S156insTProp1 is unable to increase due to the loss of DNA-binding activity. PMID: 20381582
18. These findings are consistent with a role for Pit-1 as an initiating factor in human growth hormone (hGH) locus activation during somatotrope ontogeny, acting through binding sites at the locus control region. PMID: 19427323
19. Novel association of two rare conditions Pit-1 mutation and lipoedema in a family that has not been described before. PMID: 19609847
20. Data are consistent with recruitment and an early role for Pit-1 in remodeling of the growth hormone locus control region at the constitutively open hypersensitive site III through protein-protein interaction. PMID: 20395397
21. Pit-1 regulates mammary PRL transcription by binding to the proximal PRL promoter. Pit-1 raises cyclin D1 expression before increasing PRL levels. There was a significant correlation between Pit-1 & PRL expression in 94 invasive ductal breast carcinomas. PMID: 19808898
22. Data suggest phosphorylation of Pit-1 (POU1F1) at T220 serves as a mechanism to modulate Pit-1 target genes by regulating binding of Pit-1 to monomeric (Pit-1) versus dimeric (Ets-1/Pit-1) sites on DNA PMID: 19887646
23. severe hypothyroidism and combined pituitary hormone deficiency due to a new mutation in the PIT-1 gene. the newly described mutation is inherited in an autosomal-recessive way. PMID: 11847467
24. the clinical presentation of the PIT1 mutation involves intrauterine growth retardation PMID: 11924936
25. silence in silent thyrotroph adenomas seems to be downstream to transcription of Pit-1 gene in the pathway leading to hormone secretion PMID: 12165656
26. specification of unique Pit-1 activity in the hGH locus control region PMID: 12189206
27. found that codon 24 proline in the transactivation domain as well as the POU domain of Pit-1 was crucial to recruit coactivator CREB-binding protein (CBP) for the expression of Pit-1-targeted genes. PMID: 12200420
28. full responsiveness to several signaling pathways regulating the hPRL promoter requires the B2 Pitx binding site and that Pitx factors may be part of the proteic complex involved in these regulations PMID: 12223489
29. phosphorylation of Pit-1 affects binding to transcription factor Ets-1 PMID: 12242337
30. Pit-1 which is required for generation of hormone producing cells in the anterior pituitary gland, have proved to be important in the cause of hypopituitarism in humans--REVIEW PMID: 12717343
31. that phenotypically normal cases have been reported with this mutation, our results deny the relationship between R271W and combined pituitary hormone deficiency. PMID: 12773133
32. New mutation located in the N-terminal (Q-4ter) of PIT-1 gene causing recessive combined pitutary hormone deficiency. PMID: 12932747
33. PIT1 mutations in man are associated with ...thyroid stimulating hormone and growth hormone deficiency... p. 278 PMID: 14646405
34. Mutations within POUF1 or P1T1 are associated with growth hormone, thyroid stimulating hormone and prolactin deficiency... p. 207 PMID: 14714741
35. the smad pathway and the tumor suppressor menin are key regulators of activin effects on PRL and Pit-1 expression, as well as on cell growth inhibition PMID: 15031321
36. the phenotype associated with POU1F1 mutations may be more variable, with the occasional preservation of TSH secretion in pituitary deficiency disease PMID: 15928241
37. Findings are consistent with the existence of LHX4-driven pathway leading to expression of GH through transcriptional activation of POU1F1. They argue against dominant-negative effect of mutant LHX4 proteins over normal LHX4. PMID: 15998782
38. The redistribution of co-repressor complexes by Pit-1 might represent an important mechanism by which transcription factors direct changes in cell-specific gene expression. PMID: 16030140
39. depending on its level of expression, Pit-1 may be involved in normal mammary development, breast disorders, or both PMID: 16061841
40. Data suggest that the expression of Pit-1 in cells of the alpha SU-based gonadotropin cell lineage might also lead to the expression of growth hormone, prolactin, and thyroid-stimulating hormone beta subunit. PMID: 16133148
41. CBP/p300 recruitment and Pit-1 dimerization are necessary for Pit-1 target gene activation and are important in the pathogenesis of combined pituitary hormone deficiency PMID: 16263824
42. direct interaction between the vitamin D receptor (VDR) as homodimer (without the retinoid X receptor), and the Pit-1 promoter, supporting the view that Pit-1 is a direct transcriptional target of VDR PMID: 16322098
43. findings show that activin negatively regulates the human Pit-1 gene promoter; activin effects on Pit-1 gene regulation are Smad independent and require the p38 MAPK pathway PMID: 16740974
44. Review article uses Pit-1 as an example while exploring the role of transcription factors in pituitary hormone secretion, and examining mutations involved in human anterior pituitary pathologies. PMID: 16879162
45. The growth-promoting effects of Pit-1 are at least partly due to the fact that this transcription factor prevents apoptotic cell death. PMID: 16901973
46. the Pit-1/Pit-1beta TADs are composed of multiple, modular, and transferable subdomains, including a regulatory R1 domain, a basal activation region, a selective inhibitory-Ras-responsive segment, and a beta-specific repressor domain PMID: 17021049
47. Review discusses the possibility that Pit-1-driven remodeling at nuclease-hypersensitive site (HS) III may precede that at HS I/II in the pituitary. PMID: 17047377
48. up-regulation of VDR transcription by Pit-1 is dependent on the presence of VDR protein PMID: 17456792
49. Phosphate uptake via Pit-1 is required for osteochondrogenic phenotypic change and calcification of vascular smooth muscle cells in vitro.[review] PMID: 17565274
50. novel POU1F1 splice site mutation, IVS4+1G>A, the first of its kind, in a Thai patient with combined pituitary hormone deficiency PMID: 18059085
顯示更多

收起更多
相關(guān)疾?。?/div>
Pituitary hormone deficiency, combined, 1 (CPHD1)
亞細胞定位：

Nucleus.
蛋白家族：

POU transcription factor family, Class-1 subfamily
數(shù)據(jù)庫鏈接：

HGNC: 9210

OMIM: 173110

KEGG: hsa:5449

UniGene: Hs.591654

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human